Pharmacocinétique des médicaments en insuffisance rénale : nouveautés

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nephrologie & Therapeutique

• Publication date

  2015-06-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/J.NEPHRO.2014.12.006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Consequences of Renal Failure on Non-Renal Clearance of Drugs

  2014cited by this paper
• Metformin in patients with chronic kidney disease: strengths and weaknesses.

  2013cited by this paper
• Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration.

  2013cited by this paper
• Influence of Serum in Hemodialysis Patients on the Expression of Intestinal and Hepatic Transporters for the Excretion of Pravastatin

  2012cited by this paper
• Down-Regulation of Hepatic CYP3A and CYP2C Mediated Metabolism in Rats with Moderate Chronic Kidney Disease

  2012cited by this paper
• Effects of Chronic Renal Failure on Brain Drug Transporters in Rats

  2012cited by this paper
• Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation

  2012cited by this paper
• Current Understanding of Drug Disposition in Kidney Disease

  2012cited by this paper
• Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity.

  2012cited by this paper
• Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in Rats

  2011cited by this paper
• Update on the pharmacokinetics and redox properties of protein-bound uremic toxins.

  2011cited by this paper
• Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

  2011cited by this paper
• Reduced hepatic synthesis of calcidiol in uremia.

  2010cited by this paper
• Inhibitory effects of uraemic toxins 3‐indoxyl sulfate and p‐cresol on losartan metabolism in vitro

  2010cited by this paper
• Nonrenal drug clearance in CKD: Searching for the path less traveled.

  2010cited by this paper
• Influence of renal function on the pharmacokinetics of diacerein after a single oral dose

  2010cited by this paper
• Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications

  2009cited by this paper
• ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

  2009cited by this paper
• Public Health Consequences of Chronic Kidney Disease

  2009cited by this paper
• Downregulation of hepatic acetylation of drugs in chronic renal failure.

  2008cited by this paper
• Effects of Chronic Renal Failure on Liver Drug Transporters

  2008cited by this paper
• Effects of Uremic Serum and Uremic Toxins on Hepatic Uptake of Digoxin

  2008cited by this paper
• Effect of hemodialysis on hepatic cytochrome P450 functional expression.

  2008cited by this paper
• Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats

  2007cited by this paper
• Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis

  2006cited by this paper
• EFFECT OF CHRONIC RENAL INSUFFICIENCY ON HEPATIC AND RENAL UDP-GLUCURONYLTRANSFERASES IN RATS

  2006cited by this paper
• Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure.

  2006cited by this paper
• Hemodialysis acutely improves hepatic CYP3A4 metabolic activity.

  2006cited by this paper
• Renal Clearance of Endogenous Hippurate Correlates with Expression Levels of Renal Organic Anion Transporters in Uremic Rats

  2005cited by this paper
• EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN

  2004cited by this paper
• Expression Levels of Renal Organic Anion Transporters (OATs) and Their Correlation with Anionic Drug Excretion in Patients with Renal Diseases

  2004cited by this paper
• Effect of experimental renal failure on the pharmacokinetics of losartan in rats.

  2002cited by this paper
• Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states.

  2002cited by this paper
• Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction

  2002cited by this paper
• Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure.

  2001cited by this paper
• Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure.

  2000cited by this paper
• Decreased acetylation of isoniazid in chronic renal failure

  1993cited by this paper
• Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

  1991cited by this paper
• Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment

  1976cited by this paper

• Antihyperglycemic and Antioxidative Stress Effects of Erythrophleum africanum (Fabaceae) Trunk Bark Powder Fractions on High‐Calorie Diet‐Induced Type 2 Diabetes in Rats

  2025cites this paper
• Drug Metabolism in Chronic Kidney Disease

  2020cites this paper
• Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats

  2019cites this paper
• Acquired long QT syndrome in chronic kidney disease patients

  2019cites this paper